Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Company Announcement no. 26/2016
To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 20 December 2016
Veloxis Pharmaceuticals Announces Financial Calendar for 2017
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2017.
29 March, 2017: 2016 Annual Report.
7 April, 2017: 2017 Annual General Meeting.
16 May, 2017: Q1 Interim Report – for the period 1 January to 31 March, 2017.
16 August, 2017: Q2 Interim Report – for the period 1 January to 30 June, 2017.
14 November, 2017: Q3 Interim Report – for the period 1 January to 30 September, 2017.
For more information, please contact:
Craig Alexander Collard
President & CEO
Phone: +1 919 591 3065
Email: [email protected]
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/541b8815-bce1-4a91-828e-c684383bc1e6
